Would you generalize the data from the CHANCE-2 trial to a broader clinic population given that the study was specific to Han Chinese patients?

I would not generalize to a broader population at this time but it is probably relevant in slow metabolizers of any ethnicity.

I believe the results of CHANCE-2 (Wang et al., PMID 34708996) are generalizable to non-Chinese populations. CHANCE (Wang et al., PMID 23803136), performed in China, and POINT (Johnston et al., PMID 29766750), performed worldwide but excluding China, produced strikingly similar results in dual antip...

No. I think it provides a proof of concept that in some patients clopidogrel is not as effective and in such patients, alternatives like ticagrelor should be studied.